Uneven Ground: How America Chooses Which Diseases Deserve a Fighting Chance

Every October, the United States turns pink. Storefronts, stadium lights, and social media feeds are awash in the color of breast cancer awareness—a cultural phenomenon that has raised billions of dollars and embedded early screening into the national consciousness. Meanwhile, colorectal cancer, which kills roughly as many Americans each year, struggles to generate anything close to the same level of public urgency. Colonoscopy completion rates remain stubbornly low, and the conversation around screening rarely escapes the confines of a gastroenterologist's waiting room.

This is not a coincidence. It is a pattern—one that repeats itself across American public health with troubling consistency. Certain diseases command enormous attention, funding, and community-level prevention infrastructure. Others, equally preventable and often more common, are met with collective indifference. The Prevention Project has spent considerable time examining why this disparity exists, who it harms, and what communities can do to correct it.

The Screening Landscape Is Not Flat

To understand the imbalance, it helps to look at the data plainly. According to the Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States, responsible for one in every five fatalities. Yet cardiovascular screening—blood pressure checks, cholesterol panels, blood glucose monitoring—receives a fraction of the cultural attention directed at cancer detection. Hypertension, often called the "silent killer," affects nearly half of American adults, but awareness campaigns rarely generate the fundraising galas or viral social media challenges that cancer-related initiatives do.

Similarly, hepatitis C screening—recommended for all adults born between 1945 and 1965, as well as anyone with certain risk factors—remains dramatically underutilized despite the fact that effective, curative treatments now exist. Chronic obstructive pulmonary disease, type 2 diabetes, and osteoporosis each present clear opportunities for early detection and intervention. Each is also screened for far less frequently than the burden of disease would seem to warrant.

At the same time, certain screening practices have been shown to generate more anxiety than benefit in specific populations. Prostate-specific antigen testing, for instance, has long been the subject of clinical debate, with major medical bodies issuing nuanced guidance about when it is appropriate. Yet cultural pressure and patient demand have kept PSA testing rates high even among men in age groups where evidence of net benefit is limited. The result is a system where some populations are over-screened for conditions that may not require aggressive detection while others go entirely unmonitored for diseases quietly advancing in their bodies.

Why We Fear Some Diseases More Than Others

The psychological literature offers a useful framework for understanding these disparities. Behavioral economists and public health researchers have long documented that human beings are not rational assessors of risk. We respond to threats based on how vivid, emotionally resonant, and socially reinforced they are—not necessarily how statistically probable or medically significant they might be.

Breast cancer, for example, has benefited from decades of advocacy that personalized the disease through survivor narratives, celebrity disclosures, and community fundraising. The result is what researchers sometimes call the "availability heuristic" at scale: because stories of breast cancer are readily accessible in our cultural memory, we perceive the risk as high and the imperative to screen as urgent. Colorectal cancer, by contrast, carries a social stigma rooted in the anatomy involved, making it less likely to be discussed openly and therefore less likely to trigger the same sense of personal vulnerability.

Media coverage plays an equally significant role. Studies examining health journalism have found that disease coverage is disproportionately influenced by celebrity involvement, dramatic treatment narratives, and the perceived novelty of the condition. Diseases that affect marginalized populations—hepatitis C among people who inject drugs, for instance, or diabetes in low-income communities of color—receive less sympathetic coverage and therefore less public momentum toward screening and prevention.

The Cost of Misdirected Attention

The consequences of these imbalances are not merely theoretical. When public health messaging, philanthropic funding, and clinical resources concentrate around a narrow set of diseases, the broader prevention infrastructure suffers. Community health workers may be trained almost exclusively in cancer screening outreach while lacking the tools to address cardiovascular risk. Federally qualified health centers may stock mammography referral pathways while offering inconsistent protocols for prediabetes identification.

There is also a meaningful equity dimension to this problem. Research has consistently shown that the diseases most likely to receive robust awareness campaigns are those that disproportionately affect white, middle-class Americans—or those that have attracted the advocacy energy of well-resourced communities. Conditions that fall heavily on Black, Latino, Indigenous, and low-income populations are far less likely to have the cultural infrastructure that drives screening uptake. Sickle cell disease, lupus, and certain occupational lung diseases represent only a few examples of conditions that carry enormous burden within specific communities while remaining largely invisible in national prevention conversations.

Toward a More Rational Prevention Strategy

The goal is not to diminish the genuine progress made in breast cancer awareness or to suggest that any single disease has received too much care. Rather, it is to ask whether the allocation of public health attention—across media, philanthropy, policy, and community programming—reflects the actual distribution of preventable suffering in America.

Several approaches have shown promise in rebalancing these efforts. Health departments in cities like Louisville, Kentucky, and Albuquerque, New Mexico, have begun adopting burden-of-disease frameworks that explicitly map local mortality and morbidity data onto prevention program priorities. Rather than defaulting to nationally prominent campaigns, these departments identify which conditions are most responsible for years of life lost within their specific populations and direct outreach accordingly.

Community health organizations have also begun experimenting with what might be called "bundled prevention" events—health fairs and mobile clinic days that offer screenings for multiple conditions simultaneously, reducing the cultural hierarchy that elevates one disease over another. When a community resident arrives for a free mammogram and is also offered a blood pressure check, a fasting glucose test, and a hepatitis C antibody test, the message is clear: all of your health risks matter equally, and all of them deserve your attention.

Public health communication specialists have likewise begun advocating for a shift in how prevention messaging is constructed. Rather than leading with disease-specific branding, some campaigns now emphasize the concept of screening as a universal behavior—something adults do regularly, regardless of which conditions are currently in the cultural spotlight.

A More Honest Conversation About Risk

Prevention, at its most effective, is not a popularity contest. It is a disciplined, evidence-driven effort to identify where harm is most likely to occur and to intervene before that harm becomes irreversible. When cultural forces distort that calculus—elevating certain diseases to the status of national causes while others languish in obscurity—the result is a prevention system that is simultaneously over-resourced in some areas and dangerously thin in others.

The communities best positioned to address this problem are those willing to have an honest, data-informed conversation about where their residents are actually dying prematurely and why. That conversation requires looking past awareness ribbons and celebrity endorsements toward the quieter, less glamorous work of meeting people where they are and screening for the conditions most likely to take years from their lives.

At The Prevention Project, we believe that every preventable death represents a failure of collective will—not just clinical infrastructure. Correcting the uneven ground of American screening culture is not a matter of choosing winners and losers among diseases. It is a matter of ensuring that every community, and every condition that threatens it, receives the serious, sustained attention that prevention demands.